Argenx to highlight potential first-in-class fcrn antagonist efgartigimod at upcoming neuromuscular meetings

Breda, the netherlands – october 8 , 2021 – argenx (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced the presentation of additional data from the phase 3 adapt trial of efgartigimod for the treatment of generalized myasthenia gravis (gmg). the data will be presented at two upcoming neuromuscular meetings: the american association of neuromuscular and electrodiagnostic medicine (aanem) annual meeting on october 13-16, 2021 in aurora, co and the virtual myasthenia gravis foundation of america scientific session (mgfa) on october 30, 2021.
ARGX Ratings Summary
ARGX Quant Ranking